Status:
COMPLETED
Safety and Tolerability Study of Transscleral Iontophoresis by the EyeGate® II Drug Delivery Device System
Lead Sponsor:
Eyegate Pharmaceuticals, Inc.
Conditions:
Healthy
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of a single iontophoretic dose of buffered solution administered through the EyeGate® II Drug Delivery System in healthy adult huma...
Detailed Description
This is a single center, randomized, single-masked, comparative group, safety and tolerability study of single dose levels of citrate buffer delivered through transcleral iontophoresis administered vi...
Eligibility Criteria
Inclusion
- Healthy adults
- Normal ophthalmic examination in both eyes
Exclusion
- Presence of subjective ocular symptoms
- Presence of conjunctival hyperemia, chemosis, watering, conjunctival discharge
- Ocular trauma
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT00698425
Start Date
March 1 2008
End Date
January 1 2009
Last Update
August 23 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. John's Medical College Hospital
Bangalore, Karnataka, India, 560 034